ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets tough lung cancer
Disease control Not yet recruitingThis phase 2 trial tests a new drug called AK146D1, given together with other cancer drugs, in 348 people with advanced non-small cell lung cancer that cannot be surgically removed. The study aims to see if the combination is safe and can shrink tumors. Participants will receive …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo takes on advanced lung cancer
Disease control Not yet recruitingThis study tests a new combination of two drugs, AMT116 and ivosimab, in people with advanced non-small cell lung cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18 to 75 will take part…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a common antioxidant boost chemo for advanced lung cancer?
Disease control Not yet recruitingThis study tests whether adding alpha lipoic acid (a strong antioxidant) to standard chemotherapy helps people with advanced non-small cell lung cancer. About 60 adults with stage III or IV lung cancer will take 600 mg of alpha lipoic acid daily alongside their chemo. Researchers…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Timing is everything: new trial seeks to boost lung cancer treatment by rescheduling immunotherapy
Disease control Not yet recruitingThis clinical trial is testing whether giving immunotherapy a few days after chemotherapy, instead of on the same day, can improve outcomes for people with advanced non-small cell lung cancer. The study will enroll 246 adults and compare three different timing schedules, includin…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC